Navigation Links
Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
Date:10/11/2011

12, that Omeros will initiate a second Phase 3 trial of OMS302 following discussions with regulators, that OMS302 could represent a significant advance for significant advance for both ophthalmologic surgeons and their patients, and that Omeros may have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... 2014 financial results for the period ended June 30, 2014, ... will host a conference call and webcast that day at ... slide presentation relating to the call will be available via ... Call Details To access the live conference call via ...
(Date:7/28/2014)... 28, 2014  ProteinSimple announced today that it has ... new assay allows users to detect all proteins separated ... Western users can analyze proteins without the need for ... changed protein analysis as we know it today. First, the ... - no messy gels, no transfer tanks, no blots, ...
(Date:7/28/2014)... HILDEN , Germany and ... -- , Collaboration aims to ... plasma samples to guide the use of IRESSA  for ... test will build on QIAGEN,s FDA-approved  therascreen   EGFR test ... QIAsymphony family of automated instruments  Project enabled ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
... Foundation Radiology Group (FRG), the region,s premier provider ... it has been named the Hospital Council of Western ... Pittsburgh-based radiology practice that brings the expertise of a ... across Pennsylvania and the tri-state area. By partnering with ...
... Oct. 18 Fenwal, Inc., a global medical ... safety and availability, announced today it has signed ... sell, market and distribute the AccuVein AV300 vein ... North America. (Photo:   http://photos.prnewswire.com/prnh/20101018/CG83159 ...
Cached Medicine Technology:Hospital Council of Western Pennsylvania Announces Foundation Radiology Group as Newest Partner 2Fenwal Named Exclusive Provider of AccuVein's Award-Winning Vein Illumination Device for Blood and Plasma Centers 2Fenwal Named Exclusive Provider of AccuVein's Award-Winning Vein Illumination Device for Blood and Plasma Centers 3
(Date:7/28/2014)... CW4K was among those invited to ... and Partnership for a Healthier America (PHA) ... group's DrinkUP effort, which encourages people across ... , The seven organizations added included Brita®, First 5 ... Bottle, Santa Clara Valley Water District and The California ...
(Date:7/28/2014)... To commemorate World Hepatitis Day which ... Living with a Disability magazine has published a ... include hepatitis, gastrointestinal hemorrhage, inflammatory bowel disease, short bowel ... article highlights that, in the context of receiving a ... other disabling conditions related to the digestive system must ...
(Date:7/28/2014)... 28, 2014 Building a sense of ... important. Where personal outdoor space is not possible, ... enjoy fun and exercise outside is important. That’s ... in quality commercial playground equipment from APCPLAY. , Old ... Midlothian, Virginia. It is an historic tourist location of ...
(Date:7/28/2014)... Shore Points Capital announced today that it ... Inc., through a recapitalization of the Company led by ... investor in Loftware for over nine years, a period ... provider of enterprise level software solutions for supply chain ... for us, and we are proud of everything the ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Cuidado Casero ... and hospice, PCO, PCA, and PHC in Texas, New Mexico, ... a sponsor of the North Texas Chapter of PAM’s 2014 ... the Peruvian American Medical Society. The North Texas chapter was ... and other professionals interested in improving medical care for the ...
Breaking Medicine News(10 mins):Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2
... Peru, Jan. 14 The National Cancer Coalition ... announce a pilot program to assist cancer patients ... medicines Mylotarg(TM) (gemtuzumab ozogamicin for injection) and Neumega(TM) ... Peruvian Health Ministry participated in a hand-over event ...
... to oust reformers, local union officers unopposedOAKLAND, Calif., ... Sal Rosselli and all 17 other statewide officers ... committee chair Debby Schneider. Their victory comes despite ... Stern to oust reformers in the local union ...
... Protections for Texas NursesAUSTIN, Texas, Jan. 14 ... hospitals will gain even more influence in setting appropriate ... The legislation, authored in the Senate by Sen. Jane ... Donna Howard (D-Austin), and supported by the Texas Nurses ...
... By the time they have been diagnosed with Alzheimer,s ... they cannot give informed consent to participate in research ... decision, but there is no clear policy for this ... increasingly common disease is often stalled. , But a ...
... Obesity continues to increase for women in the ... the ages of 35-44, there are approximately 3.3 million ... women who are obese. A new study published in ... there is an increased risk for midlife obesity among ...
... in French . , Montreal, January 14, 2009 ... progression of breast cancer. According to a recent study from ... in the Journal of Biological Chemistry , the protein ... the spread of tumours. Targeting this protein with drug therapy ...
Cached Medicine News:Health News:NCC and Wyeth Donation to Assist Cancer Patients in Latin America 2Health News:United Healthcare Workers Re-Elect All Statewide Officers 2Health News:Legislation Would Give Texas Nurses Even Stronger Voice in Hospital Staffing 2Health News:Legislation Would Give Texas Nurses Even Stronger Voice in Hospital Staffing 3Health News:Most support Alzheimer's research based on family consent 2Health News:Most support Alzheimer's research based on family consent 3Health News:Economic status affects obesity rates in Mexican-American and white women 2
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
... Stent may become a practice-changing technology for ... treatment of lower urinary tract symptoms (LUTS). ... retention , Men unfit for surgery , ... therapy - TUMT, TUNA, Brachytherapy, Cryotherapy , ...
Medicine Products: